- Home
- SACH vs VRCA Comparison
SACH vs VRCA Comparison
Compare SACH & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SACH | VRCA |
|---|---|---|
| Founded | 2010 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.0M | 32.7M |
| IPO Year | 2017 | 2018 |
Fundamental Metrics
Financial Performance| Metric | SACH | VRCA |
|---|---|---|
| Price | $1.15 | $7.92 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 3 | 2 |
| Target Price | ★ $2.00 | N/A |
| AVG Volume (30 Days) | 240.2K | ★ 402.7K |
| Earning Date | 11-05-2025 | 11-14-2025 |
| Dividend Yield | ★ 17.39% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $3,906,000.00 | ★ $30,829,000.00 |
| Revenue This Year | N/A | $373.65 |
| Revenue Next Year | $1.73 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 234.73 |
| 52 Week Low | $0.80 | $3.28 |
| 52 Week High | $1.40 | $9.82 |
Technical Indicators
Market Signals| Indicator | SACH | VRCA |
|---|---|---|
| Relative Strength Index (RSI) | 60.16 | 62.44 |
| Support Level | $1.00 | $7.82 |
| Resistance Level | $1.16 | $9.78 |
| Average True Range (ATR) | 0.05 | 1.18 |
| MACD | 0.02 | 0.10 |
| Stochastic Oscillator | 69.57 | 64.93 |
Price Performance
Historical ComparisonAbout SACH Sachem Capital Corp.
Sachem Capital Corp is a real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns majority of its revenue through Interest income from loans.
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.